Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)169.21
  • Today's Change0.70 / 0.42%
  • Shares traded3.40m
  • 1 Year change+2.53%
  • Beta0.8446
Data delayed at least 15 minutes, as of Mar 28 2024 20:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zoetis Inc. is an animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. It has a diversified business, commercializing products across eight core species: dogs, cats and horses (companion animals) and cattle, swine, poultry, fish and sheep (livestock); and within seven major product categories: parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics and medicated feed additives. The Company operates through two segments: the United States and International. Within each of these segments, it offers a diversified product portfolio for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America, and its products are sold in more than 100 countries.

  • Revenue in USD (TTM)8.54bn
  • Net income in USD2.34bn
  • Incorporated2012
  • Employees14.10k
  • Location
    Zoetis Inc10 Sylvan WayPARSIPPANY 07054United StatesUSA
  • Phone+1 (973) 822-7000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.zoetis.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ZTS:NYQ since
announced
Transaction
value
Adivo GmbHDeal completed15 Sep 202315 Sep 2023Deal completed-7.40%--
Data delayed at least 15 minutes, as of Mar 28 2024 20:10 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Moderna Inc6.85bn-4.71bn40.80bn5.60k--2.94--5.96-12.39-12.3917.6836.270.30938.156.011,222,857.00-21.2920.95-25.9429.5131.47---68.8432.103.36--0.03990.00-64.45119.28-156.37--46.22--
Iqvia Holdings Inc14.98bn1.36bn45.90bn87.00k34.657.5118.493.067.307.3080.4233.670.5761--4.76172,229.905.223.246.804.0734.9634.329.066.03--3.240.69110.003.987.5524.4743.397.17--
Zoetis Inc8.54bn2.34bn77.48bn14.10k33.3715.5227.379.075.075.0718.4810.900.5851.036.78605,957.4016.0214.4719.3717.1870.4769.8027.3925.772.0017.150.568226.895.747.9610.8811.1316.7124.37
Gilead Sciences, Inc.27.12bn5.66bn91.25bn18.00k16.264.0010.993.374.504.5021.5618.330.43283.955.751,506,445.008.966.7410.918.1276.0478.6420.6916.951.277.630.523481.22-0.60484.1523.370.7436-8.745.64
Regeneron Pharmaceuticals Inc13.12bn3.95bn105.64bn13.45k27.694.0524.158.0534.7634.76115.32237.410.42110.72892.39975,256.5012.6920.1814.1923.2286.1686.6330.1438.114.94--0.0943--7.7614.34-8.8710.7219.32--
Vertex Pharmaceuticals Incorporated9.87bn3.62bn107.98bn5.40k30.096.1328.4110.9413.8913.8937.8868.220.48282.106.571,827,630.0017.7119.9220.9323.6487.2187.6736.6835.853.78--0.0210.0010.5126.498.9646.5022.02--
Bristol-Myers Squibb Co45.01bn8.03bn109.66bn34.10k14.063.726.162.443.863.8621.6614.560.46894.245.011,319,824.008.383.0510.893.7676.4476.1317.867.691.3112.390.5743133.63-2.5014.8126.8410.034.927.34
Data as of Mar 28 2024. Currency figures normalised to Zoetis Inc's reporting currency: US Dollar USD

Institutional shareholders

35.96%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 202338.35m8.38%
BlackRock Fund Advisorsas of 31 Dec 202322.37m4.89%
SSgA Funds Management, Inc.as of 31 Dec 202319.32m4.22%
State Farm Investment Management Corp.as of 31 Dec 202316.34m3.57%
Capital Research & Management Co. (International Investors)as of 31 Dec 202314.68m3.21%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 202313.08m2.86%
AllianceBernstein LPas of 31 Dec 202312.57m2.75%
Geode Capital Management LLCas of 31 Dec 20239.84m2.15%
Capital Research & Management Co. (World Investors)as of 31 Dec 20239.06m1.98%
Wellington Management Co. LLPas of 31 Dec 20239.02m1.97%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.